Eosinophilic Esophagitis Clinical Trials 2023

What are the top hospitals conducting eosinophilic esophagitis research?

When it comes to advancing research and treatment options for eosinophilic esophagitis, several top hospitals are leading the way. In Cincinnati, the Cincinnati Children's Hospital Medical Center is at the forefront with four ongoing clinical trials dedicated to this condition, adding to their impressive total of 21 trials conducted since their first recorded eosinophilic esophagitis trial in 2001. The University of Pennsylvania in Philadelphia is also making significant strides, currently conducting three active trials for this condition while having completed a commendable 18 studies overall since initiating their first trial in 2011.

Meanwhile, at the Children's Hospital of Philadelphia, researchers are actively involved in three clinical trials focused on eosinophilic esophagitis. Their dedication builds upon a solid foundation of previous research efforts that have resulted in 12 conducted studies dating back to their inaugural trial in 2007. On the West Coast, Gastrointestinal Biosciences has emerged as an influential player despite being relatively new on the scene. With three ongoing eosinophilic esophagitis trials and being one of only a few institutions dedicating specific attention to this condition from as recently as2021; they hold great potential for future breakthroughs.

In addition to these established medical centers, Nature Coast Clinical Research LLC located in Inverness has shown promising contributions within its domain by actively running three clinical tests towards addressing issues surrounding eosinophilic esophagitis cases.Their approach dates back only six years ago when they launched pioneering investigations specifically tailored towards finding solutions related to such conditionsand further built momentum through completing six previous experiments.

These hospitals across different locations demonstrate unwavering commitment toward uncovering better diagnostic methods and effective treatments for patients with eosinophilic esophagitis - an immune system disorder affecting the esophagus characterized by inflammation caused by high levels of white blood cells known as eosinophils.Given that each trial brings us closer to a deeper understanding of this condition and improved care, the collective efforts of these institutions offer renewed hope for those living with eosinophilic esophagitis.

Which are the best cities for eosinophilic esophagitis clinical trials?

For those seeking clinical trials for eosinophilic esophagitis, several cities stand out as hubs of research and development. Philadelphia, Pennsylvania leads the way with 15 active trials investigating promising treatments like CC-93538, Dupilumab, and Barzolvolimab (CDX-0159). Cincinnati, Ohio follows closely behind with 12 ongoing studies focused on interventions such as CC-93538 and Dupilumab. Additionally, Boston, Massachusetts, Pennsylvania leads the way with 15 active trials investigating promising treatments like CC-93538, Dupilumab, and Barzolvolimab (CDX-0159). Cincinnati, Ohio follows closely behind with 12 ongoing studies focused on interventions such as CC-93538 and Dupilumab. Additionally, Boston, Massachusetts offers 11 active trials exploring treatments like CC-93538 and Barzolvolimab (CDX-0159), while Salt Lake City, Utah provides nine active trials researching similar options. Lastly, Iowa City, Iowa boasts eight active trials examining potential breakthroughs including CC-93538 and Cendakimab. These cities serve as beacons of hope for those affected by eosinophilic esophagitis who are eager to participate in cutting-edge clinical research.

Which are the top treatments for eosinophilic esophagitis being explored in clinical trials?

Eosinophilic esophagitis research is making strides in the quest for effective treatments. Leading the charge is dupilumab, currently being tested in three active trials dedicated to eosinophilic esophagitis. Since its introduction in 2015, it has been involved in a total of four clinical trials focused on combating this condition. Another potential contender is CC-93538, which entered the scene more recently in 2021 and is now undergoing evaluation through two ongoing eosinophilic esophagitis trials. As researchers continue their dedicated efforts, these promising treatments offer hope for individuals suffering from eosinophilic esophagitis worldwide.

What are the most recent clinical trials for eosinophilic esophagitis?

Exciting advancements are being made in the field of eosinophilic esophagitis, with recent clinical trials offering potential breakthroughs for patients. One notable trial involves an active drug specifically developed to target this condition, demonstrating promising results during its Phase 2 study. Additionally, Barzolvolimab (CDX-0159) has shown considerable efficacy in treating eosinophilic esophagitis in a Phase 2 trial. Another study is currently underway evaluating the effectiveness of EP-104IAR 4 mg, providing further insights into potential treatment options. These trials represent significant progress towards improving outcomes and quality of life for individuals living with eosinophilic esophagitis.

What eosinophilic esophagitis clinical trials were recently completed?

Several recent clinical trials have made significant progress in the field of eosinophilic esophagitis, offering hope for improved treatment options. Notably, Revolo Biotherapeutics completed a trial investigating IRL201104 in October 2021, while Ellodi Pharmaceuticals concluded their study on APT-1011 in September 2021. Allakos Inc.'s AK002 also underwent successful trials twice, once completing in May 2021 and another time concluding back in November 2018. In December 2020, both Arena Pharmaceuticals' Etrasimod and Allakos Inc.'s lirentelimab studies reached completion milestones. These advancements bring us closer to better understanding and managing eosinophilic esophagitis—a condition that causes inflammation of the esophagus—and offer promise for patients seeking relief from its burdensome impact.